Micropulse diode TSCPC consistently lowers IOP

Article

Micropulse diode transscleral cyclophotocoagulation (TSCPC) lowers IOP consistently, predictably, and with minimal ocular complications, according to a recently published study.

Micropulse diode transscleral cyclophotocoagulation (TSCPC) lowers IOP consistently, predictably, and with minimal ocular complications, according to a study recently published in Clinical & Experimental Ophthalmology.

In a randomized, comparative, explorative study, researchers from London and Singapore randomly assigned 48 hospital patients who had refractory, end-stage glaucoma to undergo diode TSCPC in micropulse mode or in continuous mode. Researchers monitored IOP, visual acuity (VA), number of medications taken and whether re-treatment was necessary. Complications included a decline in VA, prolonged anterior chamber inflammation, phthisis bulbi, scleral thinning and ocular pain.

After 12 months, a primary outcome - IOP between 6 and 21 mmHg - was noted in 75% of study participants whose cyclophotocoagulation was performed in micropulse mode and 29% who received continuous mode. Another primary outcome was a minimum 30% reduction with or without anti-glaucoma medications after 18 months. At this point in the study, this primary outcome was seen in 52% of micropulse mode patients and 30% of continuous mode participants, respectively.

Mean IOP was reduced by 45% in both groups from a baseline of 36.5 mmHg and 35.0 mmHg after a range of 16 to 19 months of follow-up. The investigators did not see significant difference in the re-treatment rates or in the number of IOP-lowering medications taken. The ocular complication rate was higher in the eyes treated in continuous wave mode.

To read an abstract of the study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.